Randomized Clinical Trial to Analyze the Efficacy of a Supplement Extracted From Persimmon on Overweight / Obesity Grade I in Subjects With Body Mass Index Greater Than 25.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Supplementation
- Sponsor
- Universidad Católica San Antonio de Murcia
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Total fat mass
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Randomized, controlled, double-blind clinical trial, with two parallel branches depending on the product consumed (experimental product and placebo product) and single-center, to measure the efficacy of a supplement extracted from Persimmon on overweight and obesity grade I in subjects with BMI over 25.
Detailed Description
The product to be consumed is a supplement extracted from the Persimmon. Participants will consume the product for 84 days. They will take one capsule before the two main meals. Subjects will have to make 3 visits to the laboratory. In the initial visit it will be verified if the subject meets the criteria required by the study. Subjects who meet the selection criteria will be randomly assigned to each of the study groups (investigational product or placebo, depending on the group to which they have been assigned). In the other two visits, the subjects will carry out the appropriate tests for taking of data colletion. These visits will be separated by 84 days of product consumption.
Investigators
Francisco Javier López Román
Principal Investigator
Universidad Católica San Antonio de Murcia
Eligibility Criteria
Inclusion Criteria
- •Subjects of both sexes aged 18-65 years.
- •Subjects with a body mass index greater than 25 and less than
- •Volunteers able to understand the clinical study and willing to comply with the study procedures and the procedures and requirements of the study.
Exclusion Criteria
- •Subjects undergoing treatment that may affect body weight.
- •Subjects with acute diseases.
- •Volunteers with a history or presence of chronic pulmonary disorders, hepatic, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, urological, neurological, psychiatric, cardiovascular, or malignant tumor pathology or disease.
- •Subjects who have undergone major surgery in the last 3 months.
- •Subjects who quit smoking in the last 6 months or who intend to quit during the study.
- •Subjects with allergies or eating disorders.
- •Volunteers who are participating in another study that involves blood draws or dietary intervention.
- •Pregnant or breastfeeding women.
Outcomes
Primary Outcomes
Total fat mass
Time Frame: From baseline to 84 days
Dual X-ray absorptiometry (DEXA), measured in grams.
Fat mass in torso
Time Frame: From baseline to 84 days
Dual X-ray absorptiometry (DEXA), measured in grams.
Fat mass in lower limbs
Time Frame: From baseline to 84 days
Dual X-ray absorptiometry (DEXA), measured in grams.
Secondary Outcomes
- Fat mass(A record of body composition will be made twotimes during the 84 days of consumption. Measures will be taken at baseline, and at 84 days. For this we will use a TANITA.)
- Muscle mass(A record of body composition will be made twotimes during the 84 days of consumption. Measures will be taken at baseline, and at 84 days. For this we will use a TANITA.)
- Percentage of fat mass(A record of body composition will be made twotimes during the 84 days of consumption. Measures will be taken at baseline, and at 84 days. For this we will use a TANITA.)
- Waist-hip perimeter(A record of body composition will be made twotimes during the 84 days of consumption. Measures will be taken at baseline, and at 84 days. For this we will use a TANITA.)
- Quality of life in people with obesity(The questionnaire will be carried out twice. The first time at the beginning and the second after carrying out 84 days of consumption of the product under study.)
- Inflammatory profile - PCR(Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of product intake.)
- Gut microbiota(Stool collection will be performed twice on subjects. The first time at the beginning and the second after 84 days of consumption of the product under study.)
- Lipidic Metabolism(Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of product intake.)
- Physical activity(An accelerometer will be placed twice on the subjects. The first time at baseline and the second after taking 84 days of consumption of the product under study)
- Nutritional assessment(The food recall will be performed twice on the subjects. The first time at the beginning and the second after carrying out 84 days of consumption of the product under study. In each one a total of 7 days will be collected.)
- Glycidic profile(Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of product intake.)
- Total antioxidant capacity of plasma(Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of product intake.)
- Inflammatory profile - IL-6(Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 84 days of product intake.)
- Liver safety variables(Hematological samples were taken before (day 0) and after consumption of the product (day 84) both in the control group and in the experimental group.)